A practical reference on heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-27. Anything still debated is marked as such rather than presented as settled.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
| Property | Value | Notes |
|---|---|---|
| Typical purity report | 95% or higher by HPLC | Area percentage at 214 nm |
| Identity confirmation | Mass spectrometry | Electrospray or MALDI |
| Powder storage | -20 C, desiccated | Protect from light |
| Solution storage | 2-8 C short term | Freeze aliquots for longer |
| Quality document | Certificate of analysis | States method and value |
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
The Chou–Fasman method is an empirical technique for the prediction of secondary structures in proteins, originally developed in the 1970s by Peter Y. Chou and Gerald D. Fasman. The method is based on analyses of the relative frequencies of each amino acid in alpha helices, beta sheets, and turns based on known protein structures solved with X-ray crystallography. From these frequencies a set of probability parameters were derived for the appearance of each amino acid in each secondary structure type, and these parameters are used to predict the probability that a given sequence of amino acids would form a helix, a beta strand, or a turn in a protein. The method is at most about 50–60% accurate in identifying correct secondary structures, which is significantly less accurate than the modern machine learning–based techniques.
Rec. ITU-R BT.1201-1 (2004) Rec. ITU-R BT.1769 (2006) Rec. ITU-R BT.2020 (2012, revised 2014) Rec. ITU-R BT.2035-0 (07/13) A reference viewing environment for evaluation of HDTV program material or completed programmes Rec. ITU-R BS.2051-0 (02/14) Advanced sound system for programme production Rec. ITU-R BT.2100 (2016) Other documents prepared or being prepared by ITU-R:
== Analysis == Ligation may also serve as a DNA analysis method. Some techniques employ rolling circle amplification. The most notable of these is described by Smolina et al., 2007 & Smolina et al., 2008 using fluorescence in situ hybridization and peptide nucleic acids. They developed and employed this technique for analyses of bacterial chromosomes.
Sources: en.wikipedia.org
=== Nuclear weapons decommissioning === Waste from nuclear weapons decommissioning is unlikely to contain much beta or gamma activity other than tritium and americium. It is more likely to contain alpha-emitting actinides such as Pu-239 which is a fissile material used in nuclear bombs, plus some material with much higher specific activities, such as Pu-238 or Po. In the past the neutron trigger for an atomic bomb tended to be beryllium and a high activity alpha emitter such as polonium; an alternative to polonium is Pu-238. For reasons of national security, details of the design of modern nuclear bombs are normally not released to the open literature. Some designs might contain a radioisotope thermoelectric generator using Pu-238 to provide a long-lasting source of electrical power for the electronics in the device. It is likely that the fissile material of an old nuclear bomb, which is due for refitting, will contain decay products of the plutonium isotopes used in it. These are likely to include U-236 from Pu-240 impurities plus some U-235 from decay of the Pu-239; due to the relatively long half-life of these Pu isotopes, these wastes from radioactive decay of bomb core material would be very small, and in any case, far less dangerous (even in terms of simple radioactivity) than the Pu-239 itself.
=== Treatment of thyrotoxicosis === Major uses of 131I include the treatment of thyrotoxicosis (hyperthyroidism) due to Graves' disease, and sometimes hyperactive thyroid nodules (abnormally active thyroid tissue that is not malignant). The therapeutic use of radioiodine to treat hyperthyroidism from Graves' disease was first reported by Saul Hertz in 1941. The dose is typically administered orally (either as a liquid or capsule), in an outpatient setting, and is usually 400–600 megabecquerels (MBq). Radioactive iodine (iodine-131) alone can potentially worsen thyrotoxicosis in the first few days after treatment. One side effect of treatment is an initial period of a few days of increased hyperthyroid symptoms. This occurs because when the radioactive iodine destroys the thyroid cells, they can release thyroid hormone into the blood stream. For this reason, sometimes patients are pre-treated with thyrostatic medications such as methimazole, and/or they are given symptomatic treatment such as propranolol. Radioactive iodine treatment is contraindicated in breast-feeding and pregnancy
== Baltimore Colts == The Baltimore Colts defensive line that included future Hall of Famers defensive end Gino Marchetti and tackle Art Donovan, along with end Don Joyce and tackle Eugene "Big Daddy" Lipscomb has also been referred to as the "'fearsome foursome'" by at least 1958. They have been called the prototype of defensive lines. In addition to Marchetti’s and Donovan’s Hall of Fame status, Lipscomb was first-team All-Pro in 1958 and 1959. Marchetti is considered among the greatest defensive ends in NFL history. The Colts won the 1958 and 1959 NFL championships over the New York Giants, the 1958 game being known as "The Greatest Game Ever Played". They played together as a line from 1956 to 1960, with defensive end Ordell Braase taking over as a starter for Joyce in 1960, and Lipscomb being traded to the Steelers before the start of the 1961 season.
Sources: en.wikipedia.org
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.
Dry powder is kept frozen, desiccated, and shielded from light. Dissolved material is aliquoted and frozen to limit freeze-thaw cycles. Short-term refrigerated storage is common for working solutions.
Russia registers it as a prescription nasal product. Most other markets classify it as a research chemical with no approved medical use. Oversight of purity and labeling is consequently minimal in those markets.
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.